HauserSLWaubantEArnoldDL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med2008; 358(7): 676–688.
2.
LiRPattersonKRBar-OrA. Reassessing B cell contributions in multiple sclerosis. Nat Immunol2018; 19(7): 696–707.
3.
SimpsonAMowryEMNewsomeSD. Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol2021; 23(7): 19.
4.
ScottiBDisantoGSaccoR, et al. Effectiveness and safety of Rituximab in multiple sclerosis: An observational study from Southern Switzerland. PLoS ONE2018; 13(5): e0197415.
5.
SalzerJSvenningssonRAlpingP, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology2016; 87(20): 2074–2081.
6.
ZeccaCBovisFNoviG, et al. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. Mult Scler2020; 26(12): 1519–1531.
MathewTJohnSKKamathV, et al. Efficacy and safety of rituximab in multiple sclerosis: Experience from a developing country. Mult Scler Relat Disord2020; 43: 102210.
